Indivior Stock Price, News & Analysis

Indivior (NASDAQ: INDV) will participate in the Stifel 2025 Healthcare Conference in New York City.

Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick will host 1x1 and group meetings and will appear in a public fireside discussion on Thursday, November 13, 2025 at 8:40 a.m. U.S. EST. Interested investors should contact their Stifel representative to schedule meetings. The fireside discussion will be available via a public webcast.

Indivior (Nasdaq: INDV) will report its third quarter 2025 financial results on Thursday, October 30, 2025 at 7:00 a.m. U.S. ET. Following the release, CEO Joe Ciaffoni and other leaders will host a live webcast presentation at 8:00 a.m. U.S. ET. The live webcast and presentation materials will be available on the company's Investors page at www.indivior.com, with a live webcast link and telephone registration option provided for participants. A replay of the presentation will be posted on www.indivior.com after the event.

Indivior (Nasdaq: INDV) published multicenter, open-label trial results in JAMA Network Open on Oct 15, 2025 showing that rapid SUBLOCADE induction (single 4 mg oral buprenorphine followed by same-day SUBLOCADE injection) was well tolerated and produced higher retention at the second injection versus standard induction (≥7 days oral buprenorphine before first injection).

Benefits were seen across the study population and were especially pronounced among fentanyl-positive participants. Administering the second SUBLOCADE injection one week after the first was well tolerated and the safety profile up to injection two was comparable between arms. Study limitations include its open-label design, which could introduce reporting bias.

Indivior (Nasdaq: INDV) has announced plans to change its corporate domicile from the U.K. to the U.S., establishing Indivior Pharmaceuticals, Inc. (IPI) as the new U.S. parent company. This strategic move follows the company's Nasdaq listing in June 2023 and subsequent delisting from the London Stock Exchange in July 2025.

The redomiciliation will be implemented through a U.K. court-sanctioned scheme of arrangement, where shareholders will receive one new IPI share for each Indivior PLC share. The transaction requires shareholder approval at an extraordinary general meeting in early December 2025, with the scheme expected to become effective in late January 2026. IPI shares will continue trading on Nasdaq under the symbol INDV.

Indivior (NASDAQ: INDV) announced its participation in two upcoming investor conferences in New York City. At the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th, CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and participate in a fireside chat at 9:15 a.m. ET. The following day, September 9th, the executives will attend the H.C. Wainwright 27th Annual Global Investment Conference for one-on-one and group meetings.

Indivior (NASDAQ: INDV) reported strong Q2 2025 financial results and raised its full-year guidance. Total net revenue reached $302 million, with SUBLOCADE net revenue growing 9% year-over-year to $209 million. The company has increased its FY 2025 guidance, raising total net revenue expectations to $1,030-$1,080 million from $955-$1,025 million, and adjusted EBITDA guidance to $275-$300 million from $220-$260 million.

Key Q2 metrics include gross margin of 83%, net income of $18 million, and diluted EPS of $0.14. The company initiated its Indivior Action Agenda focusing on SUBLOCADE growth and organizational simplification, completed its LSE delisting to trade exclusively on Nasdaq, and strengthened its executive team with new appointments.

Indivior (Nasdaq: INDV) has completed the cancellation of its secondary listing on the London Stock Exchange effective July 25, 2025 at 8:00 a.m. UK time. The delisting includes the removal from both the UK Financial Conduct Authority's Official List and the London Stock Exchange's main market for listed securities.

The company will maintain its primary listing on the Nasdaq Stock Market. To assist shareholders with this transition, Indivior has made available an FAQ document on their investor relations website.

Indivior (Nasdaq/LSE: INDV) has released results from a significant real-world study showing that their extended-release buprenorphine (BUP-XR) treatment demonstrated superior outcomes for opioid use disorder (OUD) patients. The study, published in Drug and Alcohol Dependence Reports, revealed that BUP-XR patients had 57% lower odds of emergency department visits compared to those without medication treatment.

Key findings show that BUP-XR patients experienced significantly lower hospitalization rates (3% vs 5% for daily oral treatment) and notably reduced inpatient costs - nearly five times lower than daily oral buprenorphine patients and ten times lower than untreated patients. Importantly, no opioid overdose-related ED visits were recorded in the BUP-XR group during the six-month study period, compared to 1.2% and 1% overdose rates in other groups.

Indivior (Nasdaq/LSE: INDV) has scheduled its second quarter 2025 financial results announcement for July 31, 2025 at 7:00 a.m. U.S. ET. Following the financial release, CEO Joe Ciaffoni and the leadership team will host a live webcast presentation at 8:00 a.m. U.S. ET.

Investors can access the webcast and presentation materials through the company's website at www.indivior.com. The event will also be accessible via telephone, with registration required for dial-in details. A replay of the presentation will be made available on the company's website afterward.